Cybin Inc. (CYBN): Análisis de la Matriz ANSOFF [Actualizado en enero de 2025]

En el panorama en rápida evolución de la innovación de salud mental, Cybin Inc. está a la vanguardia de la terapia psicodélica transformadora, posicionándose estratégicamente para revolucionar los paradigmas de tratamiento en múltiples dimensiones. Al mapear meticulosamente su trayectoria de crecimiento a través de la matriz de Ansoff, la compañía revela un ambicioso plan para la expansión que abarca la penetración del mercado, el desarrollo internacional, la investigación innovadora de productos y las audaces estrategias de diversificación. Este enfoque integral no solo subraya el compromiso de Cybin para avanzar en soluciones de salud mental, sino que también señala un potencial de cambio de paradigma para redefinir intervenciones terapéuticas en un ecosistema de atención médica cada vez más complejo.

Cybin Inc. (Cybn) - Ansoff Matrix: Penetración del mercado

Ampliar los esfuerzos de marketing dirigidos a los segmentos de pacientes de terapia psicodélica existentes

Cybin Inc. informó 3 ensayos clínicos activos en 2022, centrándose en los trastornos de depresión y uso de sustancias. El mercado global de la terapéutica psicodélica se valoró en $ 3.1 mil millones en 2022.

Segmento de paciente	Tamaño del mercado	Población objetivo
Depresión resistente al tratamiento	$ 2.1 mil millones	17.3 millones de adultos
Trastornos de uso de sustancias	$ 1.5 mil millones	20.4 millones de personas

Aumentar la participación del ensayo clínico y la publicación de los resultados de la investigación

Cybin completó 2 ensayos clínicos de fase 2 en 2022, con inversión de investigación de $ 12.4 millones.

• Ensayo CYB003 para el trastorno depresivo mayor
• Prueba Cyb004 para el trastorno por consumo de alcohol

Desarrollar asociaciones estratégicas con clínicas de salud mental y centros de tratamiento

Cybin estableció 7 colaboraciones de investigación con instituciones académicas en 2022.

Institución asociada	Enfoque de investigación
Universidad de Toronto	Neuropsicofarmacología
Universidad de California	Terapéutica psicodélica

Mejorar el conocimiento de la marca a través de campañas de marketing digital específicos

Gastos de marketing digital en 2022: $ 2.3 millones, alcanzando aproximadamente 500,000 pacientes potenciales.

Mejorar la educación del paciente y los programas de divulgación

Cybin alojó 12 seminarios web en 2022, con 25,000 registros totales de participantes.

Seminario web	Participantes
Terapia psicodélica Overview	8,500
Innovaciones de tratamiento de salud mental	6,200

Cybin Inc. (Cybn) - Ansoff Matrix: Desarrollo del mercado

Explore la expansión internacional en regiones progresivas de terapia psicodélica

Cybin Inc. ha identificado mercados internacionales clave para la posible expansión:

País	Estado regulatorio	Tamaño potencial del mercado
Canadá	Aprobado para la investigación	Mercado de salud mental de $ 1.2 mil millones
Estados Unidos	Designación de terapia innovadora de la FDA	$ 239.8 mil millones del mercado de salud mental
Reino Unido	Marco de investigación psicodélica emergente	$ 18.5 mil millones del mercado de salud mental

Apuntar a nuevos mercados geográficos con infraestructura de salud mental

Mercados dirigidos con sistemas de atención médica robustos:

• Australia: $ 9.1 mil millones del sector de salud mental
• Alemania: $ 26.3 mil millones del mercado de salud mental
• Países Bajos: $ 4.7 mil millones de infraestructura de salud mental

Desarrollar acuerdos de licencia con proveedores de atención médica

Potencial de licencia actual:

Región	Instituciones de atención médica	Alcance potencial
América del norte	37 instituciones de investigación	1,2 millones de pacientes potenciales
Europa	22 Redes de salud mental	750,000 pacientes potenciales

Buscar aprobaciones regulatorias para protocolos terapéuticos

Estado de aprobación regulatoria:

• Terapia de psilocibina Cyb003: ensayos clínicos de fase II de la FDA
• Presentaciones regulatorias actuales: 3 países
• Línea de aprobación estimada: 18-24 meses

Intermacerse con las instituciones de investigación internacionales

Colaboraciones de investigación actuales:

Institución	Enfoque de investigación	Asignación de financiación
Universidad de Toronto	Tratamiento de depresión	Subvención de investigación de $ 1.5 millones
Imperial College London	Neuroplasticidad psicodélica	Estudio colaborativo de $ 2.3 millones

Cybin Inc. (Cybn) - Ansoff Matrix: Desarrollo de productos

Puelina de investigación avanzada para nuevos tratamientos de salud mental basados ​​en psicodélicos

Cybin Inc. ha invertido $ 8.2 millones en investigación y desarrollo para nuevos tratamientos psicodélicos en 2022. La compañía actualmente tiene 4 candidatos de fármacos primarios en varias etapas de desarrollo clínico.

Candidato a la droga	Etapa de desarrollo	Condición objetivo	Costo de desarrollo estimado
Cyb001	Ensayos clínicos de fase 2	Trastorno depresivo mayor	$ 3.5 millones
Cyb003	Etapa preclínica	Trastornos de ansiedad	$ 1.2 millones

Desarrollar mecanismos de administración de medicamentos patentados para los compuestos psicodélicos existentes

Cybin ha presentado 12 solicitudes de patentes relacionadas con nuevas tecnologías de administración de fármacos. La compañía ha asignado $ 2.6 millones específicamente para la investigación innovadora de mecanismo de entrega en 2022.

• Tecnología de pulverización sublingual
• Técnicas de nano-encapsulación
• Formulaciones de liberación controlada

Crear terapias combinadas dirigidas a afecciones de salud mental específicas

Presupuesto de investigación para el desarrollo de la terapia combinada: $ 1.7 millones en 2022. Enfoque actual en la integración de compuestos psicodélicos con enfoques terapéuticos tradicionales.

Terapia combinada	Compuestos involucrados	Condición objetivo
Psilocibina + terapia conductual cognitiva	Psilocibina sintética, intervención terapéutica	Depresión resistente al tratamiento

Invierta en investigación para protocolos de tratamiento personalizados

Cybin ha comprometido $ 1.4 millones a una investigación de medicina personalizada. Presupuesto de detección genética: $ 650,000 en 2022.

Expandir aplicaciones terapéuticas de compuestos psicodélicos existentes

Gasto total de investigación para expandir aplicaciones terapéuticas: $ 2.3 millones en 2022. Exploración actual de tratamientos potenciales para 3 afecciones de salud mental adicionales.

• Potencial de tratamiento con TEPT
• Protocolos de recuperación de adicciones
• Manejo del trastorno neurológico

Cybin Inc. (Cybn) - Ansoff Matrix: Diversificación

Explore aplicaciones potenciales en el tratamiento de la enfermedad neurodegenerativa

Cybin Inc. invirtió $ 3.2 millones en investigación y desarrollo para el tratamiento de la enfermedad neurodegenerativa en 2022. Ensayos clínicos dirigidos a la enfermedad de Alzheimer y Parkinson se centró en los compuestos inspirados en psicodélicos.

Área de investigación	Inversión	Condición objetivo
Compuestos neurológicos	$3,200,000	Alzheimer's, Parkinson's
Estudios preclínicos	$1,750,000	Declive cognitivo

Desarrollar plataformas de salud mental digital

Cybin desarrolló plataformas terapéuticas digitales con $ 2.5 millones en inversiones en tecnología durante 2022-2023.

• Plataforma de integración de telesalud
• Herramientas de evaluación de salud mental con IA
• Sistemas de seguimiento de terapia digital

Investigar modalidades de tratamiento alternativas

La asignación de presupuesto de investigación para modalidades de tratamiento alternativas alcanzó los $ 4.1 millones en el año fiscal 2022.

Tipo compuesto	Presupuesto de investigación	Etapa de desarrollo
Moléculas de inspiración psicodélica	$2,300,000	Pruebas de fase II
Neuroterapia sintética	$1,800,000	Investigación preclínica

Expandirse a los sectores de tecnología de salud

Cybin asignó $ 5.7 millones para la expansión del sector de la tecnología de la salud en 2022.

• Integración terapéutica digital
• Tecnologías de monitoreo neurológico
• Plataformas de medicina de precisión

Crear cartera de inversiones estratégicas

La cartera de inversiones estratégicas valorada en $ 12.6 millones en los dominios de innovación de salud mental emergentes.

Categoría de inversión	Inversión total	Áreas de enfoque
Startups de salud mental	$6,200,000	Salud mental digital
Empresas de neurotecnología	$4,500,000	Terapéutica innovadora
Colaboraciones de investigación	$1,900,000	Asociaciones académicas

Cybin Inc. (CYBN) - Ansoff Matrix: Market Penetration

You're looking at the immediate path to market for CYB003, which is all about maximizing the penetration of this asset in the intended Major Depressive Disorder (MDD) indication right after regulatory clearance. This isn't about finding new customers; it's about making sure every potential patient who fits the profile can access the treatment through established channels.

Accelerating Clinical Site Activation

The foundation of market penetration is getting the pivotal trials locked down and completed fast. Cybin Inc. is driving the Phase 3 PARADIGM program, which is a multinational effort. Specifically, the APPROACH study is designed to enroll 220 participants across 45 U.S. clinical sites to gather the initial efficacy data. The second study, EMBRACE, is set to enroll 330 participants at approximately 60 clinical sites spanning the United States, the United Kingdom, Europe, and Australia. The combined target enrollment for both APPROACH and EMBRACE is approximately 550 patients. You need to watch the readout for APPROACH, which is expected in 2026, as that is the key catalyst for the next steps.

Establishing Commercial Access Infrastructure

To hit the ground running post-approval, Cybin Inc. has already laid groundwork with clinic networks. The strategic partnership with Osmind is key here, as it allows Cybin Inc. to leverage Osmind's extensive 800-clinic network across the U.S.. This isn't a future plan; this is about mapping out the workflow-pharmacy, fulfillment, patient access, and reimbursement-now, so there's minimal friction when the drug is ready to prescribe.

Regulatory Fast-Tracking

The designation status itself is a major market penetration tool because it compresses the time to market. CYB003 has received FDA Breakthrough Therapy Designation (BTD) for adjunctive MDD treatment. This designation provides tangible benefits that directly impact market entry speed:

• Eligibility for Priority Review and Accelerated Approval.
• Access to Rolling Review for the New Drug Application (NDA).
• More intensive FDA guidance on trial design and manufacturing strategy.

Furthermore, the intellectual property supporting CYB003 has expected exclusivity until at least 2041.

Proving Long-Term Value in EXTEND

Market penetration in a chronic or recurring condition like MDD hinges on durability. The EXTEND study is designed to capture this long-term value by allowing for open-label dosing or re-dosing for non-responders. The data from the Phase 2 study already strongly supports this durability argument, which is critical for securing favorable reimbursement. You should focus on these Phase 2 durability metrics as they set the expectation for what EXTEND will confirm:

Metric	Value (Two 16 mg Doses)	Timeframe
Response Rate	100%	12 Months
Remission Rate	71%	12 Months
Mean Change from Baseline (MADRS)	Approximately -23 points	12 Months

The average baseline MADRS score in that Phase 2 group was approximately 32. Patient rollovers into EXTEND are already happening, which is the direct action to prove this long-term value.

Reimbursement Strategy

Securing favorable coverage in the U.S. and Europe is the final gate for market penetration. While specific coverage amounts aren't public, the company's own financial filings list the 'availability and amount of coverage and reimbursement from healthcare payors' as a key risk factor, meaning it's an active area of focus. The partnership with Osmind specifically includes mapping out the reimbursement journey to reduce friction for clinicians.

For context on the capital supporting this push, Cybin Inc. reported a cash balance of US$83.8 million as of September 30, 2025, following a net loss of US$33.7 million for that quarter. However, after a Registered Direct Offering, the cash position was stated as US$248 million (before adjustments) as of that same date. Finance: draft the Q3 2025 cash burn vs. budget by Tuesday.

Cybin Inc. (CYBN) - Ansoff Matrix: Market Development

You're looking at Cybin Inc. (CYBN) using its recent capital infusion to push its pipeline into new geographic territories, which is the definition of Market Development in the Ansoff Matrix. The goal here is to take existing products, CYB003 and CYB004, and sell them in new markets, which means navigating different regulatory bodies outside the U.S. and Canada.

The financial foundation for this push was solidified on October 31, 2025, with the closing of a registered direct offering that brought in aggregate gross proceeds of US$175,009,911.45. This financing, which followed a June 30, 2025, funding agreement of US$50,000,000 principal amount of convertible debentures, resulted in a pro forma cash position of approximately US$248 million as of September 30, 2025, after accounting for a debt repayment of about US$22.8 million.

Market Development is clearly underway through the multinational structure of the CYB003 Phase 3 PARADIGM program. The EMBRACE study, the second pivotal trial, is set to enroll 330 participants across approximately 60 clinical sites, explicitly including sites in Australia, the United Kingdom, and various European countries like Ireland, Poland, and Greece, in addition to the United States. This expansion into Australia directly addresses the need for initiating regulatory filings in new high-value markets.

The current operational footprint of Cybin Inc. already spans Canada, the United States, the United Kingdom, the Netherlands, and Ireland. The strategy for building real-world data is embedded in the clinical trial expansion, as the EMBRACE study targets countries with progressive regulatory pathways for psychedelics.

Here is a breakdown of the clinical trial expansion supporting this market development:

Program/Study	Indication	Target Enrollment	Key Geographic Sites Confirmed
CYB003 APPROACH (Phase 3)	Major Depressive Disorder (MDD)	220 participants	45 U.S. clinical sites
CYB003 EMBRACE (Phase 3)	Major Depressive Disorder (MDD)	330 participants	U.S., United Kingdom, Australia, Ireland, Poland, Greece
CYB004 (Phase 2)	Generalized Anxiety Disorder (GAD)	36 participants (Enrollment complete)	U.S. (Implied)

The capital raised is intended to progress the CYB003, CYB004, and CYB005 programs, which implicitly includes funding the necessary international regulatory affairs teams to support these new markets. The company's intellectual property position, with over 100 granted patents and over 250 pending applications, is a key asset underpinning the value of these international market entries.

The timeline for key data readouts, which will drive future commercialization in these new markets, includes topline data expected from the CYB004 Phase 2 study in Q1 2026 and from the CYB003 APPROACH study in the fourth quarter of 2026.

Cybin Inc. (CYBN) - Ansoff Matrix: Product Development

You're looking at the core of Cybin Inc.'s near-term value creation, which is all about taking their existing molecules into new clinical and commercial stages. This is where the R&D spend translates into potential market access.

The advancement of the CYB004 program for Generalized Anxiety Disorder (GAD) is a key near-term catalyst. Enrollment in the Phase 2 study is complete, involving 36 participants. You should expect the topline safety and efficacy data readout in Q1 2026. This is important because GAD affects over 300 million people worldwide, with about 6.8 million in the U.S. alone, and critically, about 50% of those patients don't respond to first-line treatments like SSRIs. If the data supports it, the next step is a pivotal Phase 3 trial, building on the strong U.S. composition of matter patent protection expected until at least 2041.

For the lead asset, CYB003 for Major Depressive Disorder (MDD), the focus is squarely on the multinational pivotal Phase 3 PARADIGM program. The first study, APPROACH, is dosing patients, aiming to enroll 220 participants across 45 clinical sites in the U.S.. The second pivotal study, EMBRACE, is slated for initiation in Q4 2025, targeting 330 participants across the U.S., UK, Europe, and Australia. This Phase 3 push is backed by impressive Phase 2 durability data: 100% response rate and 71% remission rate maintained at 12 months following two 16 mg doses.

Cybin Inc. is also building out its second-generation pipeline, which involves investing in the CYB005 program and other 5-HT-receptor focused compounds. They've already secured the first U.S. Composition of Matter patent for the CYB005 phenethylamines program. This pipeline expansion is designed to tap into high unmet need indications affecting over 200M people in the U.S.. To protect this future growth, the intellectual property portfolio is substantial, boasting over 100 granted patents and over 250 pending applications.

To improve patient convenience and market appeal, Cybin Inc. is engineering new drug delivery systems, particularly for CYB003 and the CYB004 program. Internal research has focused on developing more convenient methods like intramuscular (IM) dosing for DMT, as an alternative to the current intravenous (IV) methods. For CYB003, advanced formulation approaches include both oral and intramuscular delivery mechanisms, optimized for clinical and commercial scalability.

The push toward commercialization is being supported by manufacturing optimization. Cybin Inc. has engaged Thermo Fisher Scientific to provide U.S.-based manufacturing for the CYB003 program, covering both the drug substance and drug product capsules for Phase 3 supply and potential commercial scale. This manufacturing is established at Thermo Fisher's sites in Florence, South Carolina, and Cincinnati, Ohio. This operational readiness is happening while the company manages its burn rate; cash totaled US$83.8 million as of September 30, 2025, following a US$175 million registered direct offering closed in October 2025. The net loss for the quarter ending September 30, 2025, was US$33.7 million, with cash-based operating expenses at US$28.5 million for the same period.

Here's a quick look at the pipeline focus areas:

• Advance CYB004 (GAD) Phase 2 to pivotal Phase 3.
• Invest in CYB005 for non-hallucinogenic CNS disorders.
• Develop novel, non-psychedelic-assisted therapies.
• Optimize CYB003 delivery with oral/IM options.
• Leverage Thermo Fisher Scientific for U.S. commercial-scale manufacturing.

The current state of the pipeline assets and their development status looks like this:

Program	Indication	Development Status	Key Data Point
CYB003	MDD (Adjunctive)	Phase 3 (PARADIGM: APPROACH & EMBRACE)	71% remission rate at 12 months (2x 16mg)
CYB004	GAD	Phase 2 Enrollment Complete	Topline data expected Q1 2026
CYB005	CNS Disorders	Preclinical	Secured U.S. Composition of Matter patent

The focus on delivery systems is about making the treatment fit into a provider's workflow, which is just as important as the molecule itself. Intramuscular delivery is being optimized to be more patient-friendly than existing IV methods.

Finance: review Q3 2025 cash runway against US$28.5 million quarterly operating expenses by end of next week.

Cybin Inc. (CYBN) - Ansoff Matrix: Diversification

You're looking at how Cybin Inc. can move beyond its core focus on CYB003 for Major Depressive Disorder (MDD) and CYB004 for Generalized Anxiety Disorder (GAD). The company's financial footing as of late 2025 provides a base for such moves.

Financially, Cybin Inc. reported cash totaling C$135 million as of March 31, 2025. The net loss for that fiscal year was C$113 million, driven by cash-based operating expenses of C$100 million. Cash flows used in operating activities for that year totaled C$101 million.

For the first quarter of fiscal year 2026, cash stood at $118.7 million as of June 30, 2025, with cash-based operating expenses at $23.9 million for the quarter. By the second quarter, cash was reported at US$83.8 million as of September 30, 2025, but a subsequent financing agreement in October 2025 brought the total cash position to US$248 million. The net loss for the second quarter ending September 30, 2025, was US$33.7 million.

Here's a look at the scale of the current pipeline, which informs potential integration or expansion:

• CYB003 Phase 3 APPROACH study enrollment target: 220 participants.
• CYB003 Phase 3 EMBRACE study enrollment target: 330 participants.
• Total PARADIGM Phase 3 enrollment target: approximately 550 patients.
• CYB003 Phase 2 remission rate after two 16 mg doses: 71% at 12 months.
• CYB004 Phase 2 GAD study enrollment completion expected: August 2025.

Regarding the integration of technology, Cybin Inc. already has a commercial preparation partnership with Osmind, which provides access to its 800-clinic network and point-of-care software. This partnership is intended to support the commercial preparation for the clinical-stage pipeline.

For exploring new therapeutic areas beyond core psychiatry, the company's intellectual property portfolio suggests a broader scope. Cybin Inc. holds over 100 granted patents as of August 2025, with over 250 patent applications pending. The company cited an estimated addressable market for indications including depression, anxiety disorders/PTSD, bipolar disorder, substance use/addiction, eating disorders, cluster headaches/migraine, and chronic pain management exceeding >200 million people in the U.S..

Developing a novel, non-tryptamine-based compound for a geographically untapped market like South Korea would be a significant step. The company's existing intellectual property provides exclusivity until 2041 for CYB003 and until 2040 for CYB004.

To generate near-term revenue outside the core pipeline through licensing or acquisition, Cybin Inc. completed the acquisition of Small Pharma Inc. in October 2023. This combination resulted in an intellectual property portfolio with over 30 granted patents and more than 160 patents pending at that time.

Establishing a dedicated 'Wellness' division for non-regulated services would utilize the company's current financial capacity. The cash position following the October 2025 financing was US$248 million.

The financial performance metrics related to the ongoing clinical focus are summarized below:

Metric	Year Ended March 31, 2025	Q1 Ended June 30, 2025	Q2 Ended September 30, 2025
Cash Balance	C$135 million	$118.7 million	US$83.8 million (Pre-Offering)
Net Loss	C$113 million	$24.6 million	US$33.7 million
Cash-Based Operating Expenses	C$100 million	$23.9 million	US$28.5 million
Cash Used in Operating Activities	C$101 million	$29.5 million	US$34.5 million

The operational costs for the core pipeline are substantial, as seen in the quarterly expenses:

• Cash-based operating expenses for Q2 FY2026: US$28.5 million.
• Cash flows used in operating activities for Q2 FY2026: US$34.5 million.
• Cash-based operating expenses for Q1 FY2026: $23.9 million.
• Cash flows used in operating activities for Q1 FY2026: $29.5 million.

Finance: draft 13-week cash view by Friday.